ArticleTranslational cancer research2025
Retrospective prognostic evaluation and single-cell transcriptomic analyses of non-small cell lung carcinoma with malignant pleural effusion.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The impact of malignant pleural effusion (MPE) and intrapleural infusion therapy on the prognosis of non-small cell lung carcinoma (NSCLC) patients receiving immunochemotherapy remains unclear. Investigating the tumor microenvironment of MPE may offer valuable insights for improving outcomes, yet current research in this area is limited. The aim of this study is to explore the impact of MPE and intrapleural infusion therapy on prognosis in the era of immunochemotherapy, and to identify potential therapeutic targets for improving the prognosis of MPE patients. Methods: This study included advanced NSCLC patients without driver mutations who underwent first-line immunochemotherapy at Shandong Cancer Hospital and Institute between December 2018 and June 2023. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints. Propensity score matching (PSM) and survival analysis were performed. Single-cell data of primary tumors (PTs) and MPE were obtained from GSE131907. This study performed cell subpopulation comparison, copy number variation (CNV) analysis of epithelial cells, differential gene expression analysis of malignant cells, gene set variation analysis (GSVA), single-cell regulatory network inference and clustering (SCENIC) analysis, and cell-cell interaction analysis. Results: A total of 116 patients with MPE and 279 patients without MPE were included in this study; after matching, each group included 112 patients. Patients with MPE had significantly shorter median PFS and OS compared to those without MPE (PFS: 8.0 Conclusions: Under immunochemotherapy, NSCLC patients with MPE still demonstrated poor prognosis. This provides an additional prognostic predictor for NSCLC patients receiving standard first-line treatment. However, intrapleural infusion of existing drugs did not improve survival in these patients. The high expression of certain genes in tumor cells from MPE may partly explain this unfavorable outcome. IRF9, which regulates type I interferon (IFN-I) signaling, was upregulated in MPE. Therefore, targeted delivery of IFN-I to the pleural cavity may offer a feasible approach for the treatment of MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.